Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: Findings in an obese, United States population

Gynecological Endocrinology

Volumn 28, Issue 10, 2012, Pages 819-822

  Johnstone, Erica B ^a   Davis, Gina ^b   Zane, Lee T ^b   Cedars, Marcelle I ^b   Huddleston, Heather G ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Cardiovascular risk; PCOS; Polycystic ovarian syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGING; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPERANDROGENISM; INFERTILITY, FEMALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OUTPATIENT CLINICS, HOSPITAL; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROSPECTIVE STUDIES; SAN FRANCISCO; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84866416528     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.671389     Document Type: Article

References (24)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997;18: 774-800.
2. Azziz R. PCOS: A diagnostic challenge. Reprod Biomed Online 2004;8:644-648.
3. Cotrozzi G, Matteini M, Relli P, Lazzari T. Hyperinsulinism and insulin resistance in polycystic ovarian syndrome: A verification using oral glucose, I.V. Glucose and tolbutamide. Acta Diabetol Lat 1983;20: 135-142.
4. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, Polson DW, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: An analysis of 263 consecutive cases. Clin Endocrinol (Oxf) 1990;32: 213-220.
5. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007;88:1389-1395.
6. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp 2003;52:908-915.
7. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48-53.
8. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: A comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352-2358.
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
10. Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, Welt CK. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009;94:4961-4970.
11. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-28.
12. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Odén A, Janson PO, Mattson LA, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57:505-513.
13. Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol 2001;145:749-755.
14. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-729.
15. Azziz R, Deal CL, Potter HD, Gargosky SE, Rosenfeld RG. Regulation of extragonadal insulin-like growth factor-binding protein-3 by testosterone in oophorectomized women. J Clin Endocrinol Metab 1994;79:1747-1751.
16. Billiar RB, Richardson D, Schwartz R, Posner B, Little B. Effect of chronically elevated androgen or estrogen on the glucose tolerance test and insulin response in female rhesus monkeys. Am J Obstet Gynecol 1987;157:1297-1302.
17. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, et al.; American Heart Association; National Heart, Lung, and Blood Institute; . Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
19. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
20. Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Müller-Wieland D, Krone W. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metab Clin Exp 1999;48:590-596.
21. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010;94:2197-2201.
22. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 2000;85:3161-3168.
23. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002;87:2870-2874.
24. Cupisti S, Giltay EJ, Gooren LJ, Kronawitter D, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril 2010;94:2647-2653.